NCT06634589 2026-03-18
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT05533775 2026-03-06
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03075696 2026-03-05
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06357676 2026-01-30
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT04787042 2024-11-15
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
Phase 1/2 Recruiting
NCT06592170 2024-09-19
MZL-001
The First Hospital of Jilin University
Phase 1/2 Recruiting